Stay updated on Zimberelimab Combo vs Pembrolizumab with Chemo in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Zimberelimab Combo vs Pembrolizumab with Chemo in NSCLC Clinical Trial page.

Latest updates to the Zimberelimab Combo vs Pembrolizumab with Chemo in NSCLC Clinical Trial page
- CheckyesterdayChange DetectedThe ClinicalTrials.gov footer now displays site revision v3.8.1 instead of v3.8.0.SummaryDifference0.0%

- Check8 days agoChange DetectedThe record now presents the STAR-121 Phase 3 trial of zimberelimab and domvanalimab with chemotherapy versus pembrolizumab with chemotherapy for untreated metastatic non-small cell lung cancer. It includes study design, eligibility criteria, outcome measures, recruitment status, and participating locations.SummaryDifference100%

- Check15 days agoChange DetectedThe site footer's revision label changed from v3.7.2 to v3.8.0. The page still displays a 403 Forbidden error instead of the study record.SummaryDifference0.2%

- Check29 days agoChange DetectedA general NIH notice about the terminology transition from “Artificial Intelligence” to “Super Intelligence” was added, and the site revision changed from v3.7.1 to v3.7.2. The study record itself remains inaccessible behind a 403 error.SummaryDifference1%

- Check43 days agoChange DetectedThe study record page displays a 403 Forbidden response and a Home link instead of study details. The site revision identifier also advances from v3.7.0 to v3.7.1.SummaryDifference0.6%

- Check57 days agoChange DetectedAccess to the study details is blocked by a 403 error. The page now shows the site header and a 403 message instead of the trial content.SummaryDifference17%

Stay in the know with updates to Zimberelimab Combo vs Pembrolizumab with Chemo in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Zimberelimab Combo vs Pembrolizumab with Chemo in NSCLC Clinical Trial page.